

ASX / Media Release

9 December 2011

---

**RHT: Provisional Patent lodged for HepaFat™**

Resonance Health is pleased to announce it has lodged a Provisional Patent Application to protect the intellectual property associated with the MRI measurement of fatty liver and registered the HepaFat™ Scan trademark. The Company is currently preparing its submission to the FDA for HepaFat™ Scan and has commenced discussions with interested parties on its potential use and license.

Resonance Health has also recorded substantial growth in the sales volumes of FerriScan®, for MRI-based measurement of liver iron overload in the current financial year. From July to November 2011 there has been a 30% month-on-month increase in the numbers of FerriScans sold, over the same period in 2010.

For further information please contact:

**Resonance Health**

Liza Dunne  
Managing Director  
T: +61 8 9286 5300  
E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

Colin McDonald  
Company Secretary  
T: +61 8 9286 5300  
E: [colinm@ferriscan.com](mailto:colinm@ferriscan.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.